In vitro intracellular trafficking of biodegradable nanoparticles dextran-spermine in cancer cell lines
by Fatemeh Abedini, Hossein Hosseinkhani, Maznah Ismail, Yi-Ru Chen, Abdul Rahman Omar, Pei Pei Chong, Abraham J. Domb
International Journal of Nanotechnology (IJNT), Vol. 8, No. 8/9, 2011

Abstract: The objective of the present study is to evaluate the effect of cationic dextran on the proliferation rate and biosynthetic activities of HT29, a human colonic adenocarcinoma, and MCF7, a human breast cancer cell line. Cationic dextran was prepared by means of reductive-amination between oxidised dextran and the natural oligoamine, spermine. Biological evaluations including cell proliferation assay, and cell cycle were studied. Flow cytometery was performed in order to determine the biological behaviour of cationic dextran after internalised into the cells. Our results clearly indicated that the cationic dextran was not toxic to the cells when the concentration was 5 μg/ml or lower. The results of the cell cycle flow cytometery indicated that the means of R2 in HT29, MCF7 and HeLa cells were less than 5 three days after treatment with 5 μg/ml of cationic dextran. We conclude that the toxicity of cationic dextran is dose dependent and it is not toxic at concentration lower than 5 μg/ml, and tolerable by the cells, and it can be used as a tool for gene delivery.

Online publication date: Fri, 22-Jul-2011

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Nanotechnology (IJNT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com